$65.75
-1.19%
2026-09-04 13:09:57 EDT-$0.79
헬스케어
생명공학
NASDAQ
활발히 거래 중
Travere Therapeutics, Inc.는 희귀 신장 및 대사 질환 치료제를 개발하는 바이오 제약 회사입니다. 주력 제품인 FILSPARI(sparsentan)는 질병 진행의 두 가지 경로(엔도텔린-1 및 ...
Travere Therapeutics, Inc.는 희귀 신장 및 대사 질환 치료제를 개발하는 바이오 제약 회사입니다. 주력 제품인 FILSPARI(sparsentan)는 질병 진행의 두 가지 경로(엔도텔린-1 및 ...
C-레벨 임원은 회사의 재무 전략과 혁신을 이끄는 응집된 리더십 팀입니다.
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
| Eric Dube | President, Chief Executive Officer & Director | USD 1,833,247 | — | 1973 | Active |
| Jula Inrig | Executive VP, Head of Research & Development and Chief Medical Officer | USD 1,011,772 | — | 1975 | Active |
| Peter Heerma | Chief Commercial Officer | USD 940,394 | 1971 | Active | |
| William E. Rote | Chief Research Officer | USD 935,108 | — | 1963 | Active |
| Christopher Cline | Chief Financial Officer | USD 929,557 | 1985 | Active | |
| Elizabeth E. Reed | Chief Legal Officer, General Counsel & Secretary | USD 713,634 | 1971 | Active | |
| Sandra Calvin | SVP & Chief Accounting Officer | — | 1966 | Active | |
| Casey Logan | Chief Business Officer | — | — | Active | |
| Angela Giannantonio | Chief People Officer | — | — | Active | |
| Nivi Nehra | Vice President of Corporate Communications & Investor Relations | — | — | Active |
| Filing Date | Year | Name | Position | Level | Salary | Bonus | Stock Award | Option Award | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | 2025 | Eric Dube, Ph.D. | President President, Chief Chief Executive Officer and Director Director | Founder / CEO | $854.25K | $0 | $3.31M | $3.31M | $964.13K | $14.87K | $8.46M |
| 2026-04-06 | 2025 | Jula Inrig, M.D. | Chief Chief Medical Officer | C-Level | $568.08K | $0 | $757.02K | $1.27M | $429.00K | $14.69K | $3.04M |
| 2026-04-06 | 2025 | Peter Heerma | Chief Chief Commercial Officer | C-Level | $527.92K | $0 | $583.11K | $738.25K | $397.50K | $14.98K | $2.26M |
| 2026-04-06 | 2025 | William E. Rote, Ph.D. | Chief Chief Research Officer | C-Level | $522.33K | $0 | $583.11K | $738.25K | $393.00K | $19.77K | $2.26M |
| 2026-04-06 | 2025 | Christopher Cline | Chief Chief Financial Officer | C-Level | $522.92K | $0 | $583.11K | $738.25K | $393.75K | $12.89K | $2.25M |
| 2026-04-06 | 2024 | Eric Dube, Ph.D. | President President, Chief Chief Executive Officer and Director Director | Founder / CEO | $822.00K | $0 | $1.61M | $1.90M | $865.20K | $14.70K | $5.20M |
| 2026-04-06 | 2024 | Jula Inrig, M.D. | Chief Chief Medical Officer | C-Level | $522.08K | $0 | $299.15K | $479.16K | $367.50K | $13.38K | $1.68M |
| 2026-04-06 | 2024 | William E. Rote, Ph.D. | Chief Chief Research Officer | C-Level | $502.83K | $0 | $299.15K | $342.26K | $352.80K | $19.60K | $1.52M |
| 2026-04-06 | 2024 | Peter Heerma | Chief Chief Commercial Officer | C-Level | $503.75K | $0 | $299.15K | $342.26K | $353.50K | $14.70K | $1.51M |
| 2026-04-06 | 2024 | Christopher Cline | Chief Chief Financial Officer | C-Level | $497.50K | $0 | $299.15K | $342.26K | $350.00K | $12.61K | $1.50M |
| 2026-04-06 | 2023 | Eric Dube, Ph.D. | President President, Chief Chief Executive Officer and Director Director | Founder / CEO | $795.83K | $0 | $3.04M | $3.13M | $588.00K | $15.44K | $7.57M |
| 2026-04-06 | 2023 | William E. Rote, Ph.D. | Chief Chief Research Officer | C-Level | $488.42K | $0 | $648.33K | $656.75K | $240.10K | $19.51K | $2.05M |
| 2026-04-06 | 2023 | Peter Heerma | Chief Chief Commercial Officer | C-Level | $487.17K | $0 | $604.80K | $656.75K | $240.10K | $15.10K | $2.00M |
| 2026-04-06 | 2023 | Jula Inrig, M.D. | Chief Chief Medical Officer | C-Level | $486.25K | $0 | $604.80K | $656.75K | $240.10K | $13.64K | $2.00M |
| 2026-04-06 | 2023 | Christopher Cline | Chief Chief Financial Officer | C-Level | $466.67K | $0 | $604.80K | $656.75K | $230.30K | $12.98K | $1.97M |
Sum of disclosed compensation by year (USD million)
Top founder/C-level executives over time (USD million)